Safety in treating bipolar disorder.
Gupta
Sanjay
S
School of Medicine and Biomedical Sciences, State University of New York at Buffalo, USA.
D018692:Antimanic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001569:Benzodiazepines; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000523:psychology; D003024:Clozapine / Q000009:adverse effects; D003920:Diabetes Mellitus / Q000139:chemically induced; D003987:Dibenzothiazepines / Q000009:adverse effects; D020820:Dyskinesias / Q000209:etiology; D006220:Haloperidol / Q000009:adverse effects; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced; D006966:Hyperprolactinemia / Q000139:chemically induced; D000077152:Olanzapine; D010890:Pirenzepine / Q000009:adverse effects / Q000031:analogs & derivatives*; D000069348:Quetiapine Fumarate; D018967:Risperidone / Q000009:adverse effects; D013881:Thioridazine / Q000009:adverse effects; D015430:Weight Gain / Q000187:drug effects
D018692:Antimanic Agents; D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; D010890:Pirenzepine; D003024:Clozapine; D006220:Haloperidol; D018967:Risperidone; D013881:Thioridazine; D000077152:Olanzapine